S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The single greatest medical breakthrough of all time? (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The single greatest medical breakthrough of all time? (Ad)
The Question of a Fed Pivot Isn't If, It's When, Here's Why
On the money: Yellen's next milestone is name on US currency
The single greatest medical breakthrough of all time? (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Are Investors Hearing The End Of Spotify's Downtrend?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The single greatest medical breakthrough of all time? (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The single greatest medical breakthrough of all time? (Ad)
The Question of a Fed Pivot Isn't If, It's When, Here's Why
On the money: Yellen's next milestone is name on US currency
The single greatest medical breakthrough of all time? (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Are Investors Hearing The End Of Spotify's Downtrend?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The single greatest medical breakthrough of all time? (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The single greatest medical breakthrough of all time? (Ad)
The Question of a Fed Pivot Isn't If, It's When, Here's Why
On the money: Yellen's next milestone is name on US currency
The single greatest medical breakthrough of all time? (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Are Investors Hearing The End Of Spotify's Downtrend?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The single greatest medical breakthrough of all time? (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The single greatest medical breakthrough of all time? (Ad)
The Question of a Fed Pivot Isn't If, It's When, Here's Why
On the money: Yellen's next milestone is name on US currency
The single greatest medical breakthrough of all time? (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Are Investors Hearing The End Of Spotify's Downtrend?
NASDAQ:EYPT

EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News

$3.03
-0.02 (-0.66%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.99
$3.20
50-Day Range
$3.03
$7.91
52-Week Range
$2.97
$15.50
Volume
95,339 shs
Average Volume
164,101 shs
Market Capitalization
$103.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

EyePoint Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
978.1% Upside
$32.67 Price Target
Short Interest
Bearish
7.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of EyePoint Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.15) to ($2.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

525th out of 1,022 stocks

Analytical Instruments Industry

16th out of 28 stocks

EYPT stock logo

About EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Stock News Headlines

EYPT EyePoint Pharmaceuticals, Inc.
EyePoint Investor Alert
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT)
See More Headlines
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Company Calendar

Last Earnings
11/02/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYPT
Employees
122
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$32.67
High Stock Price Forecast
$52.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+659.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-58,420,000.00
Net Margins
-186.02%
Pretax Margin
-186.02%

Debt

Sales & Book Value

Annual Sales
$35.31 million
Book Value
$5.44 per share

Miscellaneous

Free Float
30,034,000
Market Cap
$103.27 million
Optionable
Optionable
Beta
0.97

Social Links


Key Executives

  • Ms. Nancy S. Lurker (Age 65)
    Pres, CEO & Director
    Comp: $1.11M
  • Mr. George O. Elston (Age 57)
    Chief Financial Officer
    Comp: $743.86k
  • Dr. Jay S. Duker M.D. (Age 63)
    Chief Operating Officer
    Comp: $614.96k
  • Mr. David Scott Jones (Age 55)
    Sr. VP & Chief Commercial Officer
    Comp: $672.08k
  • Mr. Said Saim (Age 64)
    Chief Technology Officer
  • Mr. Ron I. Honig Esq.
    Chief Legal Officer & Company Sec.
  • Mr. Michael Pine (Age 46)
    Chief Corp. Devel. & Strategy Officer
  • Ms. Jennifer Leonard
    Chief People Officer & Sr. VP of IT
  • Dr. Dario A. Paggiarino (Age 65)
    Sr. VP & Chief Medical Officer
  • Ms. Isabelle Lefebvre
    Chief Regulatory Officer













EYPT Stock - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings
or view top-rated stocks.

What is EyePoint Pharmaceuticals' stock price forecast for 2023?

4 brokerages have issued 12 month price objectives for EyePoint Pharmaceuticals' stock. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they expect the company's share price to reach $32.67 in the next twelve months. This suggests a possible upside of 978.1% from the stock's current price.
View analysts price targets for EYPT
or view top-rated stocks among Wall Street analysts.

How have EYPT shares performed in 2022?

EyePoint Pharmaceuticals' stock was trading at $12.24 at the beginning of 2022. Since then, EYPT stock has decreased by 75.2% and is now trading at $3.03.
View the best growth stocks for 2022 here
.

Are investors shorting EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,790,000 shares, a drop of 9.1% from the October 31st total of 1,970,000 shares. Based on an average trading volume of 126,700 shares, the days-to-cover ratio is currently 14.1 days. Currently, 7.1% of the shares of the stock are sold short.
View EyePoint Pharmaceuticals' Short Interest
.

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our EYPT earnings forecast
.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.21. The company earned $10.01 million during the quarter, compared to analyst estimates of $10.06 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 48.00% and a negative net margin of 186.02%.

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals's stock reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?
What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.84%), Vanguard Group Inc. (4.10%), Verition Fund Management LLC (1.66%), Point72 Asset Management L.P. (1.44%), State Street Corp (1.27%) and Essex Investment Management Co. LLC (1.00%). Insiders that own company stock include George Elston and Nancy Lurker.
View institutional ownership trends
.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $3.03.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $103.27 million and generates $35.31 million in revenue each year. The company earns $-58,420,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

The company employs 122 workers across the globe.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.

This page (NASDAQ:EYPT) was last updated on 12/9/2022 by MarketBeat.com Staff